{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:18:46Z","timestamp":1792523926383,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["CPRIT RP200443"],"award-info":[{"award-number":["CPRIT RP200443"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP200443"],"award-info":[{"award-number":["RP200443"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["CPRIT-RP180672"],"award-info":[{"award-number":["CPRIT-RP180672"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA125123"],"award-info":[{"award-number":["CA125123"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA235667"],"award-info":[{"award-number":["R01CA235667"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA236615"],"award-info":[{"award-number":["R01CA236615"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA292664"],"award-info":[{"award-number":["R01CA292664"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["UG3CA290241"],"award-info":[{"award-number":["UG3CA290241"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012634","name":"Novocure UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100027495","name":"Education Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100027495","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016228","name":"The Derfner Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016228","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015127","name":"Commonwealth Foundation for Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015127","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["CA200437"],"award-info":[{"award-number":["CA200437"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022933","name":"Joanne and John Dallepezze Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022933","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.medj.2026.101149","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T14:56:19Z","timestamp":1779980179000},"page":"101149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity"],"prefix":"10.1016","volume":"7","author":[{"given":"Miguel A.","family":"Lopez-Lago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Taleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehek","family":"Ningoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyo","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan M.","family":"Burt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Offin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin K.","family":"Chintala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-2046","authenticated-orcid":false,"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101149_bib1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101149_bib2","first-page":"402","article-title":"Mesothelioma: Scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.medj.2026.101149_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fonc.2020.00101","article-title":"Preclinical Models of Malignant Mesothelioma","volume":"10","author":"Testa","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.medj.2026.101149_bib4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.medj.2026.101149_bib5","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-18-4093","article-title":"Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models","volume":"79","author":"Kukuyan","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2026.101149_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fonc.2020.00343","article-title":"Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?","volume":"10","author":"Cantini","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.medj.2026.101149_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107866","article-title":"Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial","volume":"194","author":"Bylicki","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.medj.2026.101149_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.21037\/tlcr.2017.05.02","article-title":"Immunotherapy for malignant pleural mesothelioma: current status and future directions","volume":"6","author":"Dozier","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.medj.2026.101149_bib9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/14712598.2019.1606209","article-title":"Immune checkpoint inhibition for the treatment of mesothelioma","volume":"19","author":"Nowak","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.medj.2026.101149_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101149_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.medj.2026.101149_bib12","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2026.101149_bib13","doi-asserted-by":"crossref","first-page":"CT036","DOI":"10.1158\/1538-7445.AM2019-CT036","article-title":"A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy","volume":"79","author":"Adusumilli","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2026.101149_bib14","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1200\/JCO.2019.37.15_suppl.2511","article-title":"Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent","volume":"37","author":"Adusumilli","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101149_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.6","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors","volume":"3","author":"Newick","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.medj.2026.101149_bib16","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101149_bib17","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.medj.2026.101149_bib18","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101149_bib19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medj.2026.101149_bib20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.medj.2026.101149_bib21","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.celrep.2018.10.001","article-title":"Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer","volume":"25","author":"Wang","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.medj.2026.101149_bib22","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","article-title":"LATS2 is a tumor suppressor gene of malignant mesothelioma","volume":"71","author":"Murakami","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2026.101149_bib23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1158\/2767-9764.CRC-24-0571","article-title":"PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma","volume":"5","author":"Cramer","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.medj.2026.101149_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1494111","article-title":"Combination immune checkpoint blockade as an effective therapy for mesothelioma","volume":"7","author":"Fear","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.medj.2026.101149_bib25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00109-011-0764-0","article-title":"Animal models and molecular imaging tools to investigate lymph node metastases","volume":"89","author":"Servais","year":"2011","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.medj.2026.101149_bib26","article-title":"Pre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden","volume":"14","author":"Servais","year":"2011","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.medj.2026.101149_bib27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.medj.2026.101149_bib28","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"25","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.medj.2026.101149_bib29","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1128\/MCB.25.6.2384-2394.2005","article-title":"The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression","volume":"25","author":"Xiao","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.medj.2026.101149_bib30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.medj.2026.101149_bib31","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.medj.2026.101149_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98575","article-title":"Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma","volume":"3","author":"Lee","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.medj.2026.101149_bib33","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1128\/MCB.01578-08","article-title":"Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling","volume":"29","author":"L\u00f3pez-Lago","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.medj.2026.101149_bib34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.devcel.2019.06.003","article-title":"The Hippo Signaling Pathway in Development and Disease","volume":"50","author":"Zheng","year":"2019","journal-title":"Dev. Cell"},{"key":"10.1016\/j.medj.2026.101149_bib35","doi-asserted-by":"crossref","first-page":"77872","DOI":"10.18632\/oncotarget.20845","article-title":"Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1","volume":"8","author":"Eguchi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.medj.2026.101149_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.medj.2026.101149_bib37","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4049\/jimmunol.2200278","article-title":"Mesothelium-Derived Factors Shape GATA6-Positive Large Cavity Macrophages","volume":"209","author":"Lai","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.medj.2026.101149_bib38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.it.2022.12.002","article-title":"Gata6(+) large peritoneal macrophages: an evolutionarily conserved sentinel and effector system for infection and injury","volume":"44","author":"Salm","year":"2023","journal-title":"Trends Immunol."},{"key":"10.1016\/j.medj.2026.101149_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113926","article-title":"The Hippo signaling pathway in development and regeneration","volume":"43","author":"Zhong","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.medj.2026.101149_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2023.1161995","article-title":"NF2 alteration in mesothelioma","volume":"5","author":"Sekido","year":"2023","journal-title":"Front. Toxicol."},{"key":"10.1016\/j.medj.2026.101149_bib41","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jtho.2016.06.021","article-title":"Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression","volume":"11","author":"Lievense","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.medj.2026.101149_bib42","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Marcq","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.medj.2026.101149_bib43","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.cell.2016.03.009","article-title":"A Reservoir of Mature Cavity Macrophages that Can Rapidly Invade Visceral Organs to Affect Tissue Repair","volume":"165","author":"Wang","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101149_bib44","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41598-022-04973-x","article-title":"A panel of emerging EMT genes identified in malignant mesothelioma","volume":"12","author":"Wu","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2026.101149_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adc9656","article-title":"Mechanosensation to inflammation: Roles for YAP\/TAZ in innate immune cells","volume":"16","author":"Meli","year":"2023","journal-title":"Sci. Signal."},{"key":"10.1016\/j.medj.2026.101149_bib46","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/ng1997","article-title":"SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion","volume":"39","author":"Kitamura","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.medj.2026.101149_bib47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41423-023-00974-6","article-title":"The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention","volume":"20","author":"Cambier","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.medj.2026.101149_bib48","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2159-8290.CD-22-0886","article-title":"Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma","volume":"13","author":"Danlos","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.medj.2026.101149_bib49","article-title":"The YAP\/TEAD4 transcriptional complex in intestinal macrophages promotes M2 polarization and alleviates DSS-induced colitis via the regulation of C\/EBP\u03b2","volume":"15","author":"Wang","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2026.101149_bib50","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1038\/s41467-025-59318-9","article-title":"Harnessing the FGFR2\/NF2\/YAP signaling-dependent necroptosis to develop an FGFR2\/IL-8 dual blockade therapeutic strategy","volume":"16","author":"Chen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2026.101149_bib51","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41419-023-06230-z","article-title":"Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy","volume":"14","author":"Huang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.medj.2026.101149_bib52","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/brain\/awac342","article-title":"Inhibition of YAP\/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma","volume":"146","author":"Laraba","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.medj.2026.101149_bib53","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.cell.2020.02.042","article-title":"Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression","volume":"180","author":"Devalaraja","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101149_bib54","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.ccell.2021.05.006","article-title":"Tim-4(+) cavity-resident macrophages impair anti-tumor CD8(+) T cell immunity","volume":"39","author":"Chow","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medj.2026.101149_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70340","article-title":"VSIG4 Promotes Tumour-Associated Macrophage M2 Polarization and Immune Escape in Colorectal Cancer via Fatty Acid Oxidation Pathway","volume":"15","author":"Liu","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.medj.2026.101149_bib56","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1016\/j.devcel.2025.04.011","article-title":"Targeting VSIG4(+) tissue-resident macrophages enhances T cell cytotoxicity and immunotherapy efficacy in cancer","volume":"60","author":"Ma","year":"2025","journal-title":"Dev. Cell"},{"key":"10.1016\/j.medj.2026.101149_bib57","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","article-title":"Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy","volume":"179","author":"Jiao","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101149_bib58","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The Immune Landscape of Cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2026.101149_bib59","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","article-title":"Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses","volume":"169","author":"Lavin","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101149_bib60","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.cell.2017.10.044","article-title":"Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer","volume":"171","author":"Puram","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.medj.2026.101149_bib61","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00262-018-2239-4","article-title":"Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)","volume":"67","author":"Schmid","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.medj.2026.101149_bib62","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-020-2015-4","article-title":"ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity","volume":"579","author":"Moral","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101149_bib63","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/bjc.2016.308","article-title":"Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients","volume":"115","author":"Khoja","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2026.101149_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-41431-4","article-title":"Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models","volume":"16","author":"Orozco Morales","year":"2026","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2026.101149_bib65","article-title":"TEAD inhibition alters the lung immune microenvironment and attenuates metastasis","author":"Rahhal","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.medj.2026.101149_bib66","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","article-title":"An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance","volume":"4","author":"Hagenbeek","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.medj.2026.101149_bib67","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/s41467-025-56634-y","article-title":"Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition","volume":"16","author":"Paul","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2026.101149_bib68","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1038\/s41591-025-04029-3","article-title":"YAP\/TEAD inhibitor VT3989 in solid tumors: a phase 1\/2 trial","volume":"31","author":"Yap","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101149_bib69","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194395","article-title":"NF2 loss malignantly transforms human pancreatic acinar cells and enhances cell fitness under environmental stress","volume":"136","author":"Xu","year":"2026","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2026.101149_bib70","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41388-023-02923-z","article-title":"The Hippo-YAP signaling pathway drives CD24-mediated immune evasion in esophageal squamous cell carcinoma via macrophage phagocytosis","volume":"43","author":"Zhou","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.medj.2026.101149_bib71","first-page":"3650","article-title":"Molecular alterations of the NF2 gene in hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"38","author":"Zhang","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.medj.2026.101149_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2026.102721","article-title":"The Hippo pathway in clear cell renal cell carcinoma (ccRCC): a nexus with the VHL disruption?","volume":"66","author":"Waeckel","year":"2026","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.medj.2026.101149_bib73","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.21037\/tcr-23-1179","article-title":"NF2 is a candidate diagnosis, prognostic, and immunotherapeutic biomarker: a systematic pan-cancer analysis","volume":"13","author":"Zhang","year":"2024","journal-title":"Transl. Cancer Res."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T21:10:59Z","timestamp":1785964259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026001522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":73,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666634026001522"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101149","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101149"}}